[ALNY] Alnylam Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 41.29 Change: 1.9 (4.82%)
Ext. hours: Change: 0 (0%)

chart ALNY

Refresh chart

Strongest Trends Summary For ALNY

ALNY is in the long-term up 377% in 14 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-CC5 for the treatment of complement-mediated diseases; ALN-AS1 for the treatment of hepatic porphyrias; ALN-PCS for the treatment of hypercholesterolemia; ALN-AAT for the treatment of AAT deficiency liver disease; ALN-TMP for the treatment of beta-thalassemia and iron-overload disorders; ALN-ANG for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia; and other programs. The company?s partner-based product development clinical and pre-clinical programs comprise ALN-RSV01 for the treatment of respiratory syncytial virus infection; ALN-VSP for the treatment of liver

Fundamental Ratios
Shares Outstanding EPS-4.83 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 154.11% Sales Growth - Q/Q-22.82% P/E-15.75
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-9.84% ROE-10.71% ROI
Current Ratio13.51 Quick Ratio Long Term Debt/Equity Debt Ratio0.05
Gross Margin Operating Margin-309.32% Net Profit Margin-263.44% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities598.98 M Cash From Investing Activities-341.33 M Cash From Operating Activities-26.25 M Gross Profit
Net Profit-50.78 M Operating Profit-52.22 M Total Assets1.63 B Total Current Assets1.09 B
Total Current Liabilities80.69 M Total Debt Total Liabilities132.28 M Total Revenue18.54 M
Technical Data
High 52 week148.54 Low 52 week65.07 Last close73.34 Last change0.91%
RSI28.58 Average true range5.13 Beta1.23 Volume734.61 K
Simple moving average 20 days-3.14% Simple moving average 50 days-10.23% Simple moving average 200 days-27.17%
Performance Data
Performance Week5.72% Performance Month0.47% Performance Quart-24.29% Performance Half-26.65%
Performance Year-44.58% Performance Year-to-date-42.27% Volatility daily4.85% Volatility weekly10.84%
Volatility monthly22.22% Volatility yearly76.97% Relative Volume208.92% Average Volume940.78 K
New High New Low

News

2020-02-24 05:44:30 | How biotech Alnylam plans to make a profit, and what stands in its way

2020-02-20 08:00:00 | Alnylam to Webcast Presentation at 9th Annual SVB Leerink Global Healthcare Conference

2020-02-18 07:00:00 | Alnylam Completes Enrollment of HELIOS-A Phase 3 Study of Vutrisiran for the Treatment of hATTR Amyloidosis with Polyneuropathy

2020-02-11 17:54:16 | Drug makers tap genetic test to save kids with seizures

2020-02-07 09:25:02 | Alnylam's ALNY Q4 Earnings Miss Estimates, Sales Beat

2020-02-07 07:38:24 | Edited Transcript of ALNY earnings conference call or presentation 6-Feb-20 1:30pm GMT

2020-02-06 08:00:00 | Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Period Activity

2020-02-06 06:30:00 | Alnylam Pharmaceuticals, Inc. to Host Earnings Call

2020-02-05 16:03:20 | In the highest ranks of Mass. corporate leadership, women still scarce

2020-01-31 06:00:00 | Alnylam Receives Positive CHMP Opinion for GIVLAARI™ givosiran for the Treatment of Acute Hepatic Porphyria in Adults and Adolescents

2020-01-30 12:31:05 | Earnings Preview: Alnylam Pharmaceuticals ALNY Q4 Earnings Expected to Decline

2020-01-29 12:02:48 | Industry vet Holtzman steps down; Decibel retunes strategy

2020-01-28 10:39:03 | Regeneron & Sanofi's sBLA for Dupixent Accepted by the FDA

2020-01-27 16:00:00 | Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2019 Financial Results

2020-01-16 05:29:38 | Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. NASDAQ:ALNY By 46%?

2020-01-15 05:39:57 | Alexion pushes 'high-risk, high-reward' ALS strategy amid competitive pressure

2020-01-13 10:17:03 | Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari

2020-01-12 18:00:00 | Alnylam Announces Preliminary* Fourth Quarter and Full Year 2019 Global Net Product Revenues and Provides Additional Commercial Updates

2020-01-10 16:00:00 | Alnylam Initiates Rolling Submission of New Drug Application NDA to U.S. Food and Drug Administration FDA for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 PH1

2020-01-10 14:20:41 | Cambridge startup raises $110M for re-doseable gene therapies

2020-01-10 07:00:08 | Biogen signs neuro disease drug deal with Cambridge startup

2020-01-08 09:28:31 | How Did Alnylam Pharmaceuticals, Inc. ALNY Compare Against Top Hedge Fund Stocks in 2019?

2020-01-07 08:40:56 | These 3 Healthcare Stocks Are Set to Soar in 2020, Says Cowen

2020-01-06 07:00:00 | Alnylam to Webcast Presentation at 38th Annual J.P. Morgan Healthcare Conference

2020-01-01 07:40:20 | We've made it to 2020. These are the top business issues to look for in the new year

2019-12-30 10:23:03 | Alnylam Stock Up More Than 61% YTD on Pipeline Progress

2019-12-30 09:35:02 | Is iShares MSCI USA Equal Weighted ETF EUSA a Strong ETF Right Now?

2019-12-26 05:00:00 | Pharma Companies Are Rushing to Treat a Little-Known Liver Disease. Investors Should Be Skeptical.

2019-12-24 07:30:33 | 10 Biotech M&A Targets Under The Scanner For 2020

2019-12-18 08:50:01 | Alnylam's Kidney Disease Drug Succeeds in Late Stage Study

2019-12-17 16:12:23 | Biotech Succeeds With Gene-Silencing Drug — But Its Stock Rally Fails

2019-12-17 09:50:00 | Alnylam's shares rise on late-stage rare disease results

2019-12-17 07:00:00 | Alnylam Reports Positive Topline Results from ILLUMINATE-A Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1

2019-12-16 15:42:08 | Pfizer Gets CHMP Nod for Vyndaqel Label Expansion in Europe

2019-12-13 12:00:05 | Here's Why Momentum Investors Will Love Alnylam Pharmaceuticals ALNY

2019-12-13 12:00:05 | Alnylam ALNY Moves to Buy: Rationale Behind the Upgrade

2019-12-13 09:15:02 | Guest Host Tonight

2019-12-11 05:29:49 | Sanofi to restructure Newton diabetes startup Onduo, saying it 'over-invested'

2019-12-04 16:53:09 | Trade of the 2020's: Sell Gold, Buy Biotech

2019-12-03 16:54:06 | Alnylam Pharmaceuticals, Inc. ALNY: These Hedge Funds Cashed Out Too Early

2019-12-02 08:12:15 | Alnylam Pharmaceuticals NASDAQ:ALNY Is In A Strong Position To Grow Its Business

2019-11-29 11:30:04 | The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG

2019-11-29 09:34:02 | Alnylam Gets Second Product Approval Amid Stiff Competition

2019-11-27 17:33:10 | Why Gold is Headed to Zero -- And What You Should Buy Instead

2019-11-26 09:39:02 | Alnylam Pharmaceuticals, Inc. ALNY Shares March Higher, Can It Continue?

2019-11-26 08:00:00 | Alnylam to Webcast Presentations at Upcoming December Investor Conferences

2019-11-25 09:42:25 | The Medicines Company to be Acquired by Novartis for $9.7B

2019-11-25 08:37:00 | Novartis Is Buying The Medicines Company for $9.7 Billion

2019-11-22 07:00:00 | Alnylam Announces 2020 Product and Pipeline Goals and Provides Updates at R&D Day

2019-11-21 09:54:02 | Alnylam's Givosiran Gets FDA Nod for Acute Hepatic Porphyria